These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 37689245)
1. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression. Kleinmann WN; Pruszynski JE; Adhikari EH Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245 [TBL] [Abstract][Full Text] [Related]
2. Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study. Floridia M; Dalzero S; Giacomet V; Tamburrini E; Masuelli G; Savasi V; Spinillo A; Tassis B; Franceschetti L; Degli Antoni AM; Sansone M; Guaraldi G; Vimercati A; Meloni A; Ravizza M; Infection; 2020 Apr; 48(2):249-258. PubMed ID: 31893354 [TBL] [Abstract][Full Text] [Related]
3. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review. O'Kelly B; Murtagh R; Lambert JS Ther Drug Monit; 2020 Apr; 42(2):229-244. PubMed ID: 32004247 [TBL] [Abstract][Full Text] [Related]
5. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. Yin DE; Ludema C; Cole SR; Golin CE; Miller WC; Warshaw MG; McKinney RE; PLoS One; 2020; 15(11):e0242405. PubMed ID: 33226999 [TBL] [Abstract][Full Text] [Related]
6. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. Hill A; Sawyer W HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663 [TBL] [Abstract][Full Text] [Related]
7. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695 [TBL] [Abstract][Full Text] [Related]
9. Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy. Saums MK; King CC; Adams JC; Sheth AN; Badell ML; Young M; Yee LM; Chadwick EG; Jamieson DJ; Haddad LB Obstet Gynecol; 2019 Dec; 134(6):1205-1214. PubMed ID: 31764730 [TBL] [Abstract][Full Text] [Related]
10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA; Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068 [TBL] [Abstract][Full Text] [Related]
11. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study. Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670 [TBL] [Abstract][Full Text] [Related]
12. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ; Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988 [TBL] [Abstract][Full Text] [Related]
13. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study. Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877 [TBL] [Abstract][Full Text] [Related]
14. Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Waters L; Bansi L; Asboe D; Pozniak A; Smit E; Orkin C; Fearnhill E; Dunn D; Phillips A; ; Antivir Ther; 2013; 18(2):213-9. PubMed ID: 23653911 [TBL] [Abstract][Full Text] [Related]
15. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen. Raffi F; Hanf M; Ferry T; Khatchatourian L; Joly V; Pugliese P; Katlama C; Robineau O; Chirouze C; Jacomet C; Delobel P; Poizot-Martin I; Ravaux I; Duvivier C; Gagneux-Brunon A; Rey D; Reynes J; May T; Bani-Sadr F; Hoen B; Morrier M; Cabie A; Allavena C; J Antimicrob Chemother; 2017 Dec; 72(12):3425-3434. PubMed ID: 28961719 [TBL] [Abstract][Full Text] [Related]
16. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens. Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527 [TBL] [Abstract][Full Text] [Related]
17. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903 [TBL] [Abstract][Full Text] [Related]
18. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
19. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR; Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299 [TBL] [Abstract][Full Text] [Related]